FTSE MIB
33.812,44 +41,37 (+0,12%) Dow Jones
40.589,34 +654,27 (+1,64%) Nasdaq
17.357,88 +176,16 (+1,03%) Nikkei 225
37.667,41 -202,10 (-0,53%) Petrolio
76,44 -1,84 (-2,35%) Bitcoin EUR
63.493,40 +1.352,48 (+2,18%)
AIM ImmunoTech Inc. (0A4Y.L)
| Chiusura precedente | 0,3900 |
| Aperto | 0,3675 |
| Denaro | 0,0000 x N/D |
| Domanda | 0,0000 x N/D |
| Min-Max giorno | 0,3675 - 0,3800 |
| Intervallo di 52 settimane | 0,3675 - 0,7200 |
| Volume | |
| Media Volume | 4.764 |
| Capitalizzazione | N/D |
| Beta (mensile su 5 anni) | -0,35 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -0,4040 |
| Prossima data utili | 13 ago 2024 - 19 ago 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | N/D |
GlobeNewswireAIM ImmunoTech Selected to Present at the 3rd Annual Marie Sklodowska-Curie Symposium on Cancer Research and Care
OCALA, Fla., Sept. 22, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced Chris McAleer, Ph.D., Scientific Officer of AIM will present at the 3rd Annual Marie Sklodowska-Curie Symposium on Cancer Research and Care being held at the Roswell Park Comprehensive Cancer Center in Buffalo, N.Y., September 20-22, 2023. In addition to the presentation, the Company is proud to announce its sponsorship of the event. Details for the presentation are a
- GlobeNewswire
AIM ImmunoTech Announces Report of Complete Topline Data from Roswell Park Comprehensive Cancer Center Study Evaluating Ampligen® as a Component of a Chemokine-Modulating (CKM) Regimen, with Paclitaxel, for the Treatment of Early-Stage Triple Negative Breast Cancer
Complete topline results confirm treatment was well tolerated, with promising clinical activity of pathologic complete response (pCR) + microinvasive residual disease (ypTmic) at 66%, comparable to pembrolizumab/neoadjuvant chemotherapy (NAC) Planned Phase 2 study in early-stage TNBC to determine if CKM including Ampligen may be a safe and effective alternative to pembrolizumab or in addition to pembrolizumab/NAC Results now available on ClinicalTrials.gov OCALA, Fla., Sept. 11, 2023 (GLOBE NEWS
- GlobeNewswire
AIM ImmunoTech to Present at the H.C. Wainwright 25th Annual Global Investment Conference
OCALA, Fla., Sept. 05, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that Thomas K. Equels, Chief Executive Officer of AIM, will present at the H.C. Wainwright 25th Annual Global Investment Conference being held September 11-13, 2023 in New York, NY and virtually. In addition to the presentation, management will be available to participate in virtual one-on-one meetings with qualified members of the investor community who are registere
